arrow_back Back to App

Drug Testing Reform: Non-Animal Alternatives for Faster, Safer Medicines

This new law allows pharmaceutical companies to use non-animal testing methods for drug safety and effectiveness, provided these methods meet regulatory standards. This aims to accelerate the market entry of new drugs and potentially reduce development costs, which could mean quicker access to innovative treatments for citizens.
Key points
Pharmaceutical companies can now use non-animal tests to demonstrate drug safety and effectiveness.
The change aims to speed up the approval process for new drugs and potentially lower development costs.
This could lead to faster access to new, safe, and effective medications for patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_1905
Sponsor: Rep. Boyle, Brendan F. [D-PA-2]
Process start date: 2021-03-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

AARF Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_1905.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-16.

What are the main provisions?

Key points include:

  • Pharmaceutical companies can now use non-animal tests to demonstrate drug safety and effectiveness.
  • The change aims to speed up the approval process for new drugs and potentially lower development costs.
  • This could lead to faster access to new, safe, and effective medications for patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Boyle, Brendan F. [D-PA-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health